IMDX vs REG · rev $1.9M vs P/E 34, $12.93B cap
Insight Molecular Diagnostics Inc. (IMDX) versus Regency Centers Corporation (REG) — a side-by-side from cached financials, not a winner call.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
Regency Centers Corporation (REG) is a reit - retail company listed on US.
Latest reported IMDX revenue for 2024-12-31 was $1.9M. Net income was -$60.7M. Revenue was up 25.1% from 2023-12-31 to 2024-12-31. IMDX currently screens at market cap $0.
REG does not have a complete income-statement cache yet.
IMDX currently screens at market cap $0. REG currently screens at market cap $12.93B and trailing P/E 33.5.
Not investment advice. Open the IMDX and REG stock pages for the full models.
Not investment advice.